US Supreme Court votes against Purdue opioid settlement

The US Supreme Court has narrowly voted against agreeing to a settlement with Purdue Pharma over the company’s role in the opioid crisis.

Purdue—the manufacturer of addictive painkiller Oxycontin (oxycodone) —and its owners the Sackler family, would have been protected from future opioid-related civil liability claimshad the court agreed to the $6 billion settlement, but the outcome of the vote was five to four against doing so.

Lower courts had approved the deal, which would have seen the Sacklers pay the sum over an 18-year period and give up their ownership of Purdue, with the company then emerging from bankruptcy and its profits going towards opioid abatement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical